Plymouth Meeting, Pennsylvania., July 26, 2021 / PRNewswire / -INOVIO (NASDAQ: INO) today announced that its second quarter 2021 financial results will be announced after the market closes. August 9, 2021.. After its release, INOVIO will host live conference calls and webcasts at: 4:30 pm (Eastern Standard Time) Discuss the financial results and provide general business updates on the DNA pharmaceutical platform, including the company’s ongoing vaccine development for COVID-19.

INOVIO is a biotechnology company focused on quickly bringing accurately designed DNA medicines to market to treat and protect people from infectious diseases, cancer, and HPV-related diseases. INOVIO is the first and only company to clinically demonstrate that DNA drugs can be delivered directly to cells in the body via a unique smart device to generate a robust and acceptable immune response. Specifically, INOVIO’s primary candidate, VGX-3100, was the first of two Phase 3 trials of precancerous cervical dysplasia for all evaluable subjects of REVEAL 1. High-grade cervical lesions and underlying high-risk HPV 16 and 18, meeting the primary and secondary endpoints. INOVIO is also evaluating INO-4800, a DNA vaccine candidate for COVID-19, in Phase 2 and Phase 2 clinical trials in the United States. China When Korea.. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA) / Joint Program Executive Office for Chemical, Biological, Radiology and Nuclear Defense ( JPEO-CBRND) / Department of Defense (DOD), HIV Vaccine Testing Network, International Vaccine Research Institute (IVI), Kaneka Eurogentech, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institute of Health, National Allergy Infectious Diseases Research Institute Diseases, Ology Bioservices, Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute, and Wistar Institute. For more information, please visit:

This press release includes expectations for R & D programs, including planning for the development and commercialization of DNA drugs, planned initiation and implementation of preclinical and clinical trials, and availability and timing for our business. Contains relevant specific forward-looking statements. Data from these studies and trials, and our ability to successfully manufacture and produce large numbers of product candidates with regulatory approval. Actual events or results are the result of many factors, including preclinical trials, clinical trials, product development programs and the uncertainties inherent in commercialization activities and results, and our ability to ensure sufficient manufacturing capacity. May differ from the expectations stated in. Mass production of product candidates, availability of funds to support continuous research and research to prove the safety and effectiveness of electroporation technology as a delivery mechanism, or development of viable DNA drugs , Ability to support the DNA drug pipeline, the number of collaborators to achieve the development and commercial milestones of our licensed products and product sales. This allows you to receive future payments and royalties, adequacy of capital resources, and the availability or potential of alternative therapies or treatments for the conditions we cover. Or Collaborators Including Alternatives It may be more effective or cost effective than any treatment or treatment that we and our collaborators are trying to develop.Whether such property liability issues, patent issues, and whether they or their licenses provide meaningful protection from others who use the Covered Technology, whether such ownership is enforceable or defendable, Whether they are allegedly infringing or infringing the rights of others, or able to withstand claims of invalidity, and other important things that may be needed to prosecute, protect or defend them. Whether resources can be funded or allocated, levels of corporate spending, evaluation of our technology by potential companies or other partners or collaborators, capital market conditions, impact of government medical proposals, and termination Other factors listed in the Annual Report on Form 10-K of the Year December 31, 2020Quarterly Report on Form 10-Q for the Ended Quarter March 31, 2021 And other documents to be submitted will be prepared by the Securities and Exchange Commission from time to time. Successful development, manufacture, or commercialization of product candidates in our pipeline, endorsement of final clinical trial results in support of regulatory approvals required to sell the product, or future provided here It proves that any of the information about your outlook is accurate. Forward-looking statements are stated only as of the date of this release and we undertake no obligation to update or revise these statements unless required by law.

Source INOVIO Pharmaceuticals, Inc.

INOVIO reports Q2 2021 financial results on August 9, 2021 | State

Source link INOVIO reports Q2 2021 financial results on August 9, 2021 | State

Source link